Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979106 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2PAOXGABRR1GABRR2BLM | |
| Hydrochloric Acid SCHEMBL27146943 | 0.98 | SMN1; SMN2 (0.40) | SMN1; SMN2PAOXGABRR1GABRR2BLM | |
| SCHEMBL18909606 | 0.84 | PAOX (0.43) | SMN1; SMN2PAOXTDP1TSHRNPSR1 | |
| SCHEMBL16653961 | 0.82 | PAOX (0.38) | SMN1; SMN2PAOXTDP1TSHRSIGMAR1 | |
| Hydrochloric Acid SCHEMBL20981783 | 0.82 | KDM4E (0.38) | SMN1; SMN2GABRR1GABRR2BLMTDP1 | |
| SCHEMBL2844292 | 0.82 | ALDH1A1 (0.39) | GABRR1GABRR2BLMTDP1TSHR | |
| SCHEMBL2844289 | 0.82 | ALDH1A1 (0.39) | GABRR1GABRR2BLMTDP1TSHR | |
| SCHEMBL20893359 | 0.82 | PAOX (0.38) | SMN1; SMN2PAOXTDP1TSHRSIGMAR1 | |
| SCHEMBL17426093 | 0.82 | PAOX (0.38) | SMN1; SMN2PAOXTDP1TSHRLMNA | |
| SCHEMBL19439698 | 0.82 | PAOX (0.38) | SMN1; SMN2PAOXTDP1TSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119340608-A | Separator, battery and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | claimed |
| JP-4205757-B2 | — | — | 2009-01-07 | — | — | JP | claimed |
| JP-2007536368-A | — | — | 2007-12-13 | — | — | JP | claimed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| CN-119340608-A | Separator, battery and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4441031-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC | 2013-10-17 | — | — | US | disclosed |
| US-8466165-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1746999-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | Warner-Lambert Company LLC (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005107758-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | SMN1; SMN2 2183/4885PAOX 528/4885GABRR1 3164/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | SMN1; SMN2 3718/4885PAOX 3267/4885GABRR1 3332/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | SMN1; SMN2 4141/4885PAOX 3227/4885GABRR1 2738/4885 |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | SMN1; SMN2 4599/4885PAOX 622/4885GABRR1 2321/4885 |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | SMN1; SMN2 1368/4885PAOX 3503/4885GABRR1 3689/4885 |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | SMN1; SMN2 2183/4885PAOX 528/4885GABRR1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.